• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
    • Overview
    • Cision Communications Cloud®
    • Monitoring
    • Distribution
    • Multimedia
    • Measurement & Analytics
    • IR
  • Contact
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
    Advanced Search
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company


      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos


      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics


  • Business
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation


      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors


      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital


      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News


      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications


      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities


      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters


      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco


      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications


      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys


      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine


      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories


      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry


      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy


      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women


      • People & Culture Overview
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Measurement & Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO

      Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Measurement & Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Advisory - Unauthorized products seized from EPCA Shipping Inc. in Richmond, British Columbia, may pose serious health risks Français


News provided by

Health Canada

Mar 21, 2017, 16:46 ET

Share this article

Share this article


Related Documents

Advisory - Unauthorized products seized from EPCA Shipping Inc. in Richmond, British Columbia, may pose serious health risks (CNW Group/Health Canada)
View PDF
Advisory - Unauthorized products seized from EPCA Shipping Inc. in Richmond, British Columbia, may pose serious health risks (CNW Group/Health Canada)

OTTAWA, March 21, 2017 /CNW/ - Issue
Health Canada is advising Canadians that it has seized several unauthorized health products from EPCA Shipping Inc. at 1115-11871 Horseshoe Way, Richmond BC (see list below). The products are promoted to treat cancer, infertility, respiratory diseases, enlarged thyroid and erectile dysfunction, and are labelled to contain various prescription drugs that may pose serious risks to the health of Canadians. EPCA Shipping Inc. is the Canadian distribution centre for www.extremepeptides.com.

Who is affected

  • Consumers who have bought or used these products.

Affected products

  • Anastrozole
  • Clenbuterol
  • Clomiphene
  • Ketotifen
  • Letrozole
  • Sildenafil
  • T3 (Liothyorine)
  • Tadalafil
  • Tamoxifen
  • Toremifene

What consumers should do

  • Stop using these products. Consult with your health care professional if you have used these products and have health concerns.
  • Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit DIN, DIN-HM or NPN. You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
  • Report adverse events to health products to Health Canada by calling toll-free at 1‑866‑234‑2345, or by reporting online, by mail or by fax.
  • Report complaints about health products to Health Canada by calling toll-free at 1‑800‑267‑9675, or complete an online complaint form.

What Health Canada is doing
Health Canada seized the products from the distributor, and is working with Canada Border Services Agency to prevent further importation of these products. Should additional distributors be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Background
Anastrozole is a prescription drug used to treat postmenopausal women with breast cancer. It should be used only under the supervision of a doctor experienced in the use of cancer drugs. Anastrozole should not be used by pregnant or breast-feeding women, and should not be used by premenopausal women or children. Serious side effects include severe skin reactions (Stevens-Johnson syndrome), allergic reaction with swelling of the face, lips, tongue and/or throat that may cause difficulty swallowing and/or breathing, angina, liver inflammation (hepatitis), and increased blood calcium levels.

Clenbuterol is a veterinary drug used to treat respiratory diseases in horses. It is not authorized for human use in Canada. Serious side effects include seizure, heart attack, psychosis, or damage to skeletal muscle. Other side effects include irregular heartbeat, increased blood pressure, tremors, nervousness, nausea, increased blood sugar, headache, and dizziness.

Clomiphene is a prescription drug used in women to treat some types of infertility. It should be used only under the supervision of a doctor experienced in the management of gynecologic or endocrine disorders. Clomiphene should not be used during pregnancy. It should not be used in patients with current or past liver disease, with unusual menstrual bleeding with an unknown cause, with a type of cancer that is made worse by hormones, or in patients with an ovarian cyst (except those with polycystic ovary syndrome). Serious side effects include ovarian hyperstimulation syndrome (over-stimulation of the ovaries), allergic reaction, blurry vision or spots or flashes in front of the eyes, stroke, liver problems, sudden and severe headaches, mental illness such as psychosis, and pancreatitis (inflammation of the pancreas). Other side effects include hot flashes, abdominal discomfort (distension, bloating, or pain), and ovarian enlargement.

Ketotifen is a prescription drug used as an add-on medication in the treatment of chronic asthma in children. It should be used only under the supervision of a health care professional. Ketotifen should not be used by pregnant or breastfeeding women. Serious side effects include convulsions, bladder inflammation, increased liver enzymes, liver inflammation (hepatitis), and severe skin reactions. Other side effects include sedation, weight gain, rash, irritability, nervousness, mouth dryness, dizziness, nausea, and headaches.

Letrozole is a prescription drug used to treat breast cancer in postmenopausal women. It should be used only under the supervision of a health care professional. Letrozole should not be used by premenopausal, pregnant or breast-feeding women, or children or adolescents under 18 years of age. It reduces blood estrogen levels, which may reduce bone mineral density and lead to bone loss (osteoporosis) and fractures. Other serious side effects include pain in the muscles, bones and joints, joint stiffness, depression, chest pain or heart attack, stroke, blood clots, swelling, allergic reaction, low level of white blood cells, cataracts, hepatitis, and severe skin disorders.

Sildenafil is a prescription drug used to treat erectile dysfunction. It should not be used by individuals taking any kind of nitrate drug (e.g. nitroglycerine) as it can cause potentially life-threatening low blood pressure. Individuals with heart problems are at increased risk of cardiovascular side effects such as heart attack, stroke, chest pain, high blood pressure and abnormal heartbeat. Other possible side effects of using sildenafil include headache, facial flushing, indigestion, dizziness, abnormal vision, and hearing loss.

T3 (also known as Liothyronine) is a prescription drug used to treat hypothyroidism or enlarged thyroid gland. It should be used only under the supervision of a health care professional. Liothyronine should not be used in patients with uncorrected adrenal gland underactivity or in patients who have had a heart attack. It should not be used to treat obesity or for weight loss. At normal doses it does not reduce body weight and at higher doses it can produce serious side effects, such as heart failure or shock. Side effects include headache, excessive sweating, fatigue, increased appetite, fever, nervousness, anxiety, irritability, insomnia, irregular heartbeat, chest pain, diarrhea, and menstrual irregularities.

Tadalafil is a prescription drug used to treat erectile dysfunction. It should not be used by individuals taking any kind of nitrate drug (such as nitroglycerine) as it can cause potentially life-threatening low blood pressure. Individuals with heart problems are at increased risk of cardiovascular side effects such as heart attack, stroke, chest pain, high blood pressure and abnormal heartbeat. Other side effects include headache, facial flushing, indigestion, dizziness, abnormal vision, and hearing loss.

Tamoxifen is a prescription drug used to treat breast cancer. It should be used only under the supervision of a health care professional. Tamoxifen should not be used by pregnant women. Serious side effects include uterine cancers, stroke, blood clots, cataracts or damage to the retina of the eye, muscle pain, bone pain, increased blood calcium, and severe skin rashes or allergic reactions. Other side effects include nausea, vomiting, fatigue, fluid retention, vaginal bleeding, hot flashes, anemia, uterine fibroids (noncancerous growths), bald spots, and fatty liver.

Toremifene is a prescription drug used to treat breast cancer in postmenopausal women. It is not authorized for use in Canada. Common side effects include hot flashes, sweating, nausea, dizziness, swelling, pain, and vomiting. Serious side effects include abnormal cell growth in the uterine lining. Other side effects include vaginal bleeding, chest pain, fatigue, back pain, headache, skin discoloration, weight gain, anorexia, insomnia, constipation, difficulty breathing, weakness, tremors, vertigo, itching, scarring or clouding of the eye, and blood clots.

For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.

To learn more about purchasing drugs online, visit Canada.ca.

SOURCE Health Canada

For further information: Media Enquiries: Health Canada, (613) 957-2983; Public Enquiries: (613) 957-2991, 1-866 225-0709

Modal title

Organization Profile

Health Canada

    Also from this source

  • Government of Canada supports expansion of innovative safer...

  • Health Canada and the European Medicines Agency publish clinical...

  • /R E P E A T -- Notice to the media - Government of Canada to...

Related Organization(s)

Government of Canada

    Also from this source

  • Invitation to media - Élisabeth Brière to announce investment to...

  • Helping workers in New Brunswick develop the skills they need to...

  • Government of Canada supports expansion of innovative safer...

    Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET

    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices

    Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

    About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers

    My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision


Products


About


My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2021 CNW Group Ltd. All Rights Reserved. A Cision company.